Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06878248 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer
A Phase 1 study of Hormone Receptor-Positive Breast Cancer and Breast Cancer Metastatic, sponsored by Calibr, a division of Scripps Research.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 5
- Study locations
NCT06878248 is a Phase 1 study of Hormone Receptor-Positive Breast Cancer and Breast Cancer Metastatic that is actively recruiting participants, run by Calibr, a division of Scripps Research. The registered enrollment target is 20 participants, below the 187-participant average among 23 other Hormone Receptor-Positive Breast Cancer trials with a reported enrollment target (89% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT06878248, a Phase 1 study of Hormone Receptor-Positive Breast Cancer and Breast Cancer Metastatic, is actively recruiting participants, sponsored by Calibr, a division of Scripps Research.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 5
- Study locations
Study Summary
The goal of this clinical trial is to evaluate CLBR001 and ABBV-461 as a treatment for patients with locally advanced or metastatic breast cancer. The goals are to establish the safety and efficacy of the combination therapy while establishing the optimal biologic doses. Patients will be administered a single infusion of CLBR001 cells followed by cycles of ABBV-461 with regular assessments of safety and disease response to treatment.
Conditions Studied
Interventions
- BIOLOGICAL Two Component Product CLBR001 + ABBV-461
Study Locations (5)
Georgia
- Augusta University Medical Center - Augusta
Indiana
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center - Indianapolis
New York
- Roswell Park Cancer Institute - Buffalo
Virginia
- University of Virginia - Charlottesville
Washington
- Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-04-17 |
| Est. Completion | 2028-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06878248
The ClinicalTrials.gov registry entry for NCT06878248 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 187-participant average among 23 other Hormone Receptor-Positive Breast Cancer trials with a reported enrollment target (89% lower). The listed sponsor is Calibr, a division of Scripps Research, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Hormone Receptor-Positive Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Two Component Product CLBR001 + ABBV-461 is the first listed.
NCT06878248 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Georgia, Indiana, New York.
Frequently Asked Questions
What is clinical trial NCT06878248 about?
NCT06878248 is a clinical study titled "A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer". The goal of this clinical trial is to evaluate CLBR001 and ABBV-461 as a treatment for patients with locally advanced or metastatic breast cancer. The goals are to establish the safety and efficacy of the combination therapy while establishing the optimal biologic doses. Patients will be administer...
What is the current status of trial NCT06878248?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2025-04-17. Estimated completion is 2028-11.
What conditions does trial NCT06878248 study?
This clinical trial studies the following conditions: Hormone Receptor-Positive Breast Cancer, Breast Cancer Metastatic, Triple Negative Breast Cancer (TNBC), Malignant Neoplasm of Breast, HER2 + Breast Cancer.
What interventions are being tested in trial NCT06878248?
The interventions under investigation include: Two Component Product CLBR001 + ABBV-461 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06878248?
This trial is sponsored by Calibr, a division of Scripps Research, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06878248 being conducted?
This trial has 5 study locations across Georgia, Indiana, New York, Virginia, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hormone Receptor-Positive Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
RECRUITING · Phase 1
-
A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
RECRUITING · Phase 1
-
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
RECRUITING · Phase 1
-
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
RECRUITING · Phase 1
-
Study of XB010 in Subjects With Solid Tumors
RECRUITING · Phase 1
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
Explore more on PlainTrial
Hormone Receptor-Positive Breast Cancer
All registered trials for this condition
Breast Cancer Metastatic
All registered trials for this condition
Georgia
All trials with a study site in Georgia
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.